Autoantibodies | Prevalence | Thrombotic events | |
---|---|---|---|
No | Yes | ||
IgG aCL medium/high titres | 101/258 (39.1%) | 95/244 (38.9%) | 6/14 (42.9%) |
IgM aCL medium/high titres | 74/258 (28.7%) | 69/244 (28.3%) | 5/14 (35.7%) |
IgG anti-β2GPI medium/high titres | 104/258 (40.3%) | 99/244 (40.6%) | 5/14 (35.7%) |
IgM anti-β2GPI medium/high titres | 79/258 (30.6%) | 74/244 (30.3%) | 5/14 (35.7%) |
Lupus anticoagulants | 130/258 (50.4%) | 119/244 (48.8%) | 11/14 (78.6%)* |
aPL antibody category I | 130/258 (50.4%) | 121/244 (49.6%) | 9/14 (64.3%) |
aPL antibody category II | 128/258 (49.6%) | 123/244 (50.4%) | 5/14 (35.7%) |
Antinuclear antibodies | 163/258 (63.2%) | 154/244 (63.1%) | 9/14 (64.3%) |
Anti-double strand DNA antibodies | 33/255 (26.4%) | 31/241 (12.9%) | 2/14 (14.3%) |
Anti-extractable nuclear antigen antibodies | 52/258 (12.9%) | 48/244 (19.7%) | 4/14 (28.6%) |
↵* Statistically significant (p<0.05).
aCL, anticardiolipin antibodies; anti-β2GPI, anti-β2-glycoprotein I antibodies.